Cargando…

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin

Adenomyoepithelioma (AME) of the breast is an uncommon tumor characterized by its dual differentiation into luminal cells and myoepithelial cells. In most cases these tumors have a benign clinical course, but distant metastases have been reported. We present the case of a 51-year-old woman diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Suee, Oh, Sung Yong, Kim, Sung-Hyun, Lee, Ji Hyun, Kim, Dae Cheul, Cho, Se Heon, Lee, Miri, Kim, Hyo-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705093/
https://www.ncbi.nlm.nih.gov/pubmed/26770248
http://dx.doi.org/10.4048/jbc.2015.18.4.400
Descripción
Sumario:Adenomyoepithelioma (AME) of the breast is an uncommon tumor characterized by its dual differentiation into luminal cells and myoepithelial cells. In most cases these tumors have a benign clinical course, but distant metastases have been reported. We present the case of a 51-year-old woman diagnosed with malignant AME. The patient underwent a right modified radical mastectomy, and pathological examination confirmed the diagnosis of malignant AME. Ten months after the operation, multiple hepatic, pleural, and abdominal wall metastases were detected. A number of palliative chemotherapeutic agents were tried, including anthracycline and taxanes. However, the disease continued to progress, and superior vena cava syndrome developed as a result of direct tumor invasion. The patient received salvage eribulin monotherapy. After two cycles of this treatment, her clinical symptoms were ameliorated, and a computed tomography scan showed a partial response. Eribulin chemotherapy was thus effective in treating malignant AME in this case.